1) When did you first hear of Medicon Valley and why did you decide to become a member of the Medicon Valley Alliance?
As a leading hub for life science research, the Medicon Valley has been a key focus for Fios Genomics’ international development. We’ve been supporting the work of several companies in the region since 2022 and have always seen strong alignment with our capabilities and mission.
We became aware of the Medicon Valley Alliance through attendance at their events such as the Oncology Network, where the value of these meetings, particularly the focus on knowledge sharing and collaboration within the MVA community, was clear from the start.
Joining the MVA will give us the chance to deepen our involvement in the region, build new collaborations and help more researchers bring breakthrough science and innovation to patients.
2) How do you think your bioinformatics expertise can help Medicon Valley based companies?
For a vibrant life science cluster like the Medicon Valley, which has a mixture of both emerging and more mature companies, our expertise in data analysis from discovery to clinical stages makes us an excellent strategic partner that can provide biological and actionable insights at every step of the therapeutic development process.
For example, at discovery and pre-clinical stages, we often help to identify and prioritize targets or uncover drug mechanisms of action. At clinical stages, we frequently provide exploratory analyses of clinical trial data to inform biomarker strategy. These projects typically involve integrating clinical and biomarker data to identify associations between clinical variables (e.g. treatment response, survival outcomes or dosage) and biological readouts (e.g. immune or mutational data). This approach helps to build a comprehensive understanding of how different patient groups respond to treatment. Depending on the hypotheses tested, the resultant biomarker profiles can inform subsequent strategic decisions, such as patient recruitment or dose optimization.
Overall, our bioinformatics expertise supports robust, data-driven decision making that accelerates development timelines and reduces risk, maximising the potential for clinical success.
3) How does the fact that you are an SME Climate Hub committed business come into play?
As a committed member of the SME Climate Hub, Fios Genomics has pledged to halve our greenhouse gas emissions by 2030 and reach Net Zero by 2045 or sooner. This commitment is embedded into our business operations, planning, and culture. We are integrating environmental considerations into every stage of planning, from international travel optimization to hybrid and low-carbon event formats consideration, using venues with strong sustainability credentials, and measuring the emissions impact of our activities.
Being part of the SME Climate Hub also gives us access to tools, frameworks, and a global community of like-minded organizations, which helps us make practical, data-informed decisions. It ensures that our efforts to grow internationally are not only commercially strategic, but also climate-conscious and future-facing.